Hoth Therapeutics Inc HOTH

Healthcare Biotechnology

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

NDAQ:HOTH - Post by User

Hoth Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by 7Twiggyon Jan 18, 2024 12:49pm

52 Views

Post# 35833924

One third of the float traded

You must be talking about a different stock. This one has a 4.5 million float and has traded 1.5 million shares or about one third of the shares out. That is one heck of a lot of volume. With positive news this could easily move to double digit numbers. My home run holding. Might even be a take out target.

<< Previous

Bullboard Posts

Next >>

Eminent acquires promising Nevada gold project